United Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for United Therapeutics (UTHR).

Price Target Range — 12 Quarters

Analyst Consensus — 16 Analysts

14Buy

1Hold

1Sell

Consensus RatingBuy# Analysts16Avg. Consensus PT$553Upside to Avg. PT-8.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 28, 2026	JP Morgan	Jessica Fye	PT Cut	Overweight	$710→$695
Oct 22, 2026	RBC Capital	Lisa Walter	PT Cut	Outperform	$708→$697
Oct 19, 2026	Leerink Partners	Roanna Ruiz	PT Raise	Outperform	$685→$725
Oct 8, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$677→$708
Oct 7, 2026	Morgan Stanley	Terence Flynn	PT Raise	Equal-Weight	$515→$566
Oct 1, 2026	BTIG	Julian Harrison	Upgrade	Neutral→Buy	$728
Sep 24, 2026	Goldman Sachs	Andrea Newkirk	Initiate	Sell	$321
Aug 6, 2026	RBC Capital	Lisa Walter	PT Cut	Outperform	$704→$677
Jul 23, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$685→$687
Jul 10, 2026	B of A Securities	Greg Harrison	PT Cut	Neutral	$620→$613
Jul 7, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$701→$704
May 7, 2026	RBC Capital	Lisa Walter	PT Cut	Outperform	$707→$701
May 7, 2026	Wells Fargo	Benjamin Burnett	Upgrade	Equal-Weight→Overweight	$575→$738
Apr 10, 2026	Morgan Stanley	Terence Flynn	PT Raise	Equal-Weight	$471→$519
Mar 31, 2026	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$600→$660
Mar 31, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Equal-Weight	$486→$575
Mar 31, 2026	B of A Securities	Greg Harrison	PT Raise	Neutral	$569→$626
Mar 30, 2026	TD Cowen	Joseph Thome	PT Raise	Buy	$575→$660
Mar 23, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Equal-Weight	$466→$486
Mar 12, 2026	Cantor Fitzgerald	Olivia Brayer Saunders	PT Raise	Overweight	$525→$625

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $695

JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and lowers the price target from $710 to $695.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $697

RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $708 to $697.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on United Therapeutics, Raises Price Target to $725

Leerink Partners analyst Roanna Ruiz maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $685 to $725.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $708

RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $677 to $708.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on United Therapeutics, Raises Price Target to $566

Morgan Stanley analyst Terence Flynn maintains United Therapeutics (NASDAQ:UTHR) with a Equal-Weight and raises the price target from $515 to $566.

Benzinga Newsdesk

This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Analysts upgraded BJRI, UTHR, OXY, BP and REGN, raising ratings and/or price targets.

Avi Kapoor

United Therapeutics Corp

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

United Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $695

PRO
RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $697

PRO
Leerink Partners Maintains Outperform on United Therapeutics, Raises Price Target to $725

PRO
RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $708

PRO
Morgan Stanley Maintains Equal-Weight on United Therapeutics, Raises Price Target to $566

This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

People Also Watch

People Also Watch

United Therapeutics Corp

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

United Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $695

PRORBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $697

PROLeerink Partners Maintains Outperform on United Therapeutics, Raises Price Target to $725

PRORBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $708

PROMorgan Stanley Maintains Equal-Weight on United Therapeutics, Raises Price Target to $566

This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

People Also Watch

People Also Watch

PRO
JP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $695

PRO
RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $697

PRO
Leerink Partners Maintains Outperform on United Therapeutics, Raises Price Target to $725

PRO
RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $708

PRO
Morgan Stanley Maintains Equal-Weight on United Therapeutics, Raises Price Target to $566